Post by Bionorica SE

How is phytotherapy evolving in response to changes in legislation and health policies? 🌱 This question was addressed by the Corporate Advisory Board of the Society for Phytotherapy (GPT) during its regular meeting at Bionorica in Neumarkt. The focus was on current scientific developments, political conditions and strategic questions regarding the positioning of phytotherapy in Germany and Europe. 🔬  Participants included representatives from companies such as Schwabe Group, WALA, PhytoLab, G. Pohl-Boskamp GmbH & Co. KG, Engelhard Arzneimittel GmbH & Co. KG and Bayer Vital, as well as organisations including the @Bundesverband der Pharmazeutischen Industrie (BPI) and Pharma Deutschland. 🤝  Ongoing dialogue within the industry is crucial for the further development and strengthening of phytotherapy, and makes a significant contribution through collaboration between science, politics, and healthcare. 🌱💬